TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429579 | PMC |
| http://dx.doi.org/10.4161/onci.19532 | DOI Listing |
Publication Analysis
Top Keywords
trail-lymphocytes epcamxcd3
8
bispecific antibody
8
cancer cells
8
combining forces
4
forces hit
4
cancer
4
hit cancer
4
cancer stem
4
cells
4
stem cells
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!